

**1 INTRODUCTION**

1.1	BACKGROUND.....	11
1.2	SCOPE OF THIS GUIDE .....	11
1.3	KEY CONCEPTS OF THIS GUIDE .....	12
1.4	USING THIS GUIDE .....	18

**2 INTERPRETATION OF THE REGULATORY BASIS FOR FACILITY REQUIREMENTS**

2.1	INTRODUCTION.....	21
2.2	SCOPE .....	22
2.3	DEFINITIONS .....	22
2.4	REGULATORY CONSIDERATIONS.....	23
2.5	GENERAL CONCEPTS .....	25

**3 MANUFACTURING OPERATIONS AND ACTIVITIES**

3.1	INTRODUCTION.....	33
3.2	OPEN VERSUS CLOSED SYSTEMS .....	34
3.3	“BIOBURDEN-CONTROLLED PROCESSING” .....	35
3.4	PYROGEN-CONTROLLED PROCESSING .....	38
3.5	SEGREGATION AND FLOW.....	38
3.6	CONSIDERATIONS FOR MULTI-PRODUCT OPERATIONS .....	40
3.7	VIRAL CLEARANCE .....	42
3.8	STAGE OF PRODUCT DEVELOPMENT .....	44
3.9	OPERATIONAL UPSET .....	45
3.10	OPERABILITY AND MAINTAINABILITY .....	45
3.11	CLEANING AND HOUSEKEEPING CONSIDERATIONS .....	48

**4 PROCESS AND EQUIPMENT**

4.1	INTRODUCTION.....	51
4.2	TYPICAL BIOPHARMACEUTICAL PROCESSES .....	52
4.3	CRITICAL PROCESS VARIABLES .....	52
4.4	GENERAL CONSIDERATIONS FOR EQUIPMENT DESIGN .....	53
4.5	SPECIFIC EQUIPMENT DESIGN CONSIDERATIONS .....	61
4.6	SUMMARY .....	67

**5 PROCESS SUPPORT AND UTILITIES**

5.1	INTRODUCTION.....	69
5.2	REGULATORY ISSUES .....	70
5.3	SYSTEM IMPACT DESCRIPTIONS .....	71
5.4	SYSTEM LAYOUT AND ROUTING .....	73
5.5	SPECIFIC SERVICE CONSIDERATIONS.....	73

# TABLE OF CONTENTS

## 6 FACILITY

6.1	INTRODUCTION .....	83
6.2	PROCESS CONSIDERATIONS .....	83
6.3	OPERATIONAL CONSIDERATIONS .....	86
6.4	FACILITY LAYOUT CONSIDERATIONS .....	88
6.5	OPERATIONAL SUPPORT .....	93
6.6	AREA ENVIRONMENT .....	96
6.7	ARCHITECTURE AND FINISHES .....	105
6.8	DISCRETIONARY CONSIDERATIONS .....	105

## 7 PROCESS CONTROLS AND AUTOMATION

7.1	INTRODUCTION .....	107
7.2	BIOPHARMACEUTICAL AUTOMATION ISSUES .....	108
7.3	LEVEL OF AUTOMATION .....	110
7.4	BIOPHARMACEUTICAL UNIT OPERATIONS .....	113
7.5	CONTROL SYSTEMS MAINTENANCE .....	116
7.6	VALIDATION OF BIOPHARMACEUTICAL AUTOMATION SYSTEMS .....	117
7.7	OTHER SYSTEMS .....	118

## 8 COMMISSIONING AND QUALIFICATION

8.1	INTRODUCTION .....	119
8.2	IMPACT ASSESSMENT .....	119
8.3	QUALIFICATION .....	124

## 9 APPENDIX - EUROPEAN ASPECTS

9.1	INTRODUCTION (GENERAL) .....	125
9.2	WATER QUALITY .....	127
9.3	BIOCONTAMINANT AND ENVIRONMENTAL PROTECTION .....	128
9.4	ENVIRONMENTAL IMPACT ISSUES .....	131
9.5	CHROMATOGRAPHY SKID SHARING .....	132
9.6	QUALIFICATION AND VALIDATION .....	132

## 10 APPENDIX - NIH LEVELS

10.1	BIOSAFETY LEVELS IN LABORATORIES .....	133
10.2	NIH GOOD LARGE SCALE PRACTICES (GLSP) .....	135

## 11 PRODUCT PROTECTION CONTROL STRATEGY .....

## 12 PROCESS TECHNOLOGY

12.1	"PROCESS FLOW DIAGRAMS" .....	139
12.2	SINGLE-USE TECHNOLOGY .....	142

**13 ADDITIONAL FACILITY INFORMATION**

13.1 TYPICAL UNIT OPERATIONS IN A BIOPHARMACEUTICAL FACILITY ..... 147  
13.2 FACILITY LAYOUT CONCEPT DIAGRAMS ..... 148  
13.3 CLOSED PROCESSES ..... 156  
13.4 LAYOUT FOR MULTI-LEVEL PROCESSING ..... 157  
13.5 GOWNING FACILITIES ..... 159  
13.6 ADDITIONAL HVAC INFORMATION ..... 159

**14 GLOSSARY, ABBREVIATIONS, AND ACRONYMS**

14.1 GLOSSARY ..... 167  
14.2 ABBREVIATIONS AND ACRONYMS ..... 186

**15 BIBLIOGRAPHY ..... 189**

